12/23
05:16 pm
ctor
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
12/23
04:30 pm
ctor
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Medium
Report
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
12/10
04:59 pm
ctor
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
12/10
04:30 pm
ctor
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Low
Report
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
12/9
08:30 am
ctor
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
High
Report
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
12/4
08:37 am
ctor
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Low
Report
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
12/1
01:16 pm
ctor
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) [Yahoo! Finance]
Low
Report
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) [Yahoo! Finance]
12/1
12:00 pm
ctor
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Low
Report
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
11/25
07:03 pm
ctor
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
Medium
Report
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
11/25
08:00 am
ctor
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
High
Report
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
11/21
08:48 am
ctor
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration [Yahoo! Finance]
High
Report
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration [Yahoo! Finance]
11/21
08:37 am
ctor
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Medium
Report
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
11/20
01:33 pm
ctor
Citius Oncology (NASDAQ:CTOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Citius Oncology (NASDAQ:CTOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
05:27 am
ctor
When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? [Yahoo! Finance]
High
Report
When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? [Yahoo! Finance]
10/20
08:37 am
ctor
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Medium
Report
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
10/16
08:47 am
ctor
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Low
Report
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
10/7
09:03 am
ctor
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe [Yahoo! Finance]
Low
Report
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe [Yahoo! Finance]
10/7
08:47 am
ctor
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
Medium
Report
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe